CNS Neuroscience &Therapeutics, Volume 32, Issue 1, January 2026.Immune checkpoint inhibitors are associated with rare but severe paraneoplastic syndromes, particularly in lung cancer patients. PS onset shows a bimodal pattern, with increased severity seen in combination therapies like durvalumab plus tremelimumab.
Bufu Tang +12 more
wiley +1 more source
Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR-TKIs (ML41256): A Multicenter, Prospective, Single-Arm, Phase 2 Trial. [PDF]
Cancer MedFang W +9 more
europepmc +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 228-240, January 2026.Data science approaches have been increasingly implemented in healthcare big data to evaluate the safety and effectiveness of drugs. Association discovery is a data mining approach that finds potentially associated elements in high‐dimensional data. We present a novel implementation of the association discovery approach in longitudinal healthcare data ...
George S. Q. Tan +6 more
wiley +1 more source
Extended Follow-Up Analysis of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Real-World Multicenter Prospective Cohort Study. [PDF]
Thorac CancerSong Y +12 more
europepmc +1 more source
Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers
Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.Evidence supporting bevacizumab in ovarian cancer and predictive biomarkers: highlighting opportunities to improve patient selection and advance personalised treatment strategies. Abstract Angiogenesis, driven by the vascular endothelial growth factor (VEGF)/VEGFR signalling axis under hypoxic conditions, is one of the hallmarks of ovarian cancer (OC),
Maria Rosaria Lamia +6 more
wiley +1 more source
Patient Characteristics, Treatment Patterns, and Outcomes in Unresectable Hepatocellular Carcinoma Treated with First-Line Systemic Therapy in the United States. [PDF]
Cancers (Basel)Tran NH +7 more
europepmc +1 more source
Molecular and immune biomarker testing in squamous-cell lung cancer: Effect of current and future therapies and technologies [PDF]
, 2018 Bradley, Jeffrey D, et al,
core +1 more source
Synergistic Strategies in Systemic Therapy for Advanced Hepatocellular Carcinoma
Global Challenges, Volume 10, Issue 1, January 2026.This article comprehensively examines the evolving landscape of systemic therapy for advanced hepatocellular carcinoma. It covers the progress in tyrosine kinase inhibitors and immune checkpoint inhibitors, analyzes the efficacy of novel combination strategies, and discusses current challenges like drug resistance and the lack of biomarkers.
Yongxin Yu +5 more
wiley +1 more source
Comparison of efficacy and safety of first-line immunotherapy combined with chemotherapy in extensive-stage small cell lung cancer, a retrospective study. [PDF]
Sci RepDong X, Yao X, Li R, Li Y, Li Y.
europepmc +1 more source